UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews Prof. Maria De Santis (DE) about the result of the final analysis of the phase III, open-label, randomised POTOMAC trial: Durvalumab (D) in combination with Bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). 

This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.